The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Fibroblast growth factor receptor 1 (FGFR1) gene copy number gain in adenocarcinoma and squamous cell carcinoma of the lung.
Ximing Tang
No relevant relationships to disclose
Yuwen Xue
No relevant relationships to disclose
Xinying Su
Employment or Leadership Position - AstraZeneca
Nusrat Harun
No relevant relationships to disclose
Yiran Cai
No relevant relationships to disclose
Carmen Behrens
No relevant relationships to disclose
Vassiliki Papadimitrakopoulou
No relevant relationships to disclose
David Blowers
Stock Ownership - AstraZeneca
Cesar Moran
No relevant relationships to disclose
Neda Kalhor
No relevant relationships to disclose
David C. Rice
Consultant or Advisory Role - Olympus America
Garry Beran
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
J. Jack Lee
No relevant relationships to disclose
Elaine Kilgour
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Ignacio Ivan Wistuba
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Johnson & Johnson; Pfizer; Roche; Sanofi
Research Funding - AstraZeneca; Bayer; Genentech; Merck; Myriad Genetics